Skip to main content

Table 2 The best corrected visual acuity (BCVA) results from patients with chronic or recurrent central serous chorioretinopathy before and after different doses of photodynamic therapy

From: One-year results of half-dose versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy

LogMAR BCVA

Half-dose(1) (mean±SD)

One-third-dose(2) (mean±SD)

P-value(1)–(2)

At baseline a

0.41±0.37

0.40±0.41

0.893

At 1 month b

0.32±0.34

0.36±0.41

0.690

At 3 months c

0.29±0.33

0.35±0.41

0.623

At 6 months d

0.24±0.32

0.31±0.36

0.541

At 12 months e

0.24±0.34

0.30±0.43

0.526

P-value

a-b; p = 0.002, a-c, p < 0.001

a-d, p < 0.001, a-e, p < 0.001

a-b; p =0.419, a-c, p= 0.216

a-d; p =0.038, a-e; p =0.028

 
  1. a,b,c,d: Linear fixed- and random-effects models
  2. (1)–(2): Linear fixed- and random-effects models
  3. Abbreviations: SD standard deviation
Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us